Paulson & Co’s Blueprint Medicines BPMC Stock Holding History

Paulson & Co’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-65,800	Closed	-$3.33M	–	59
2017 Q2	$3.33M	Buy	+65,800	New	+$2.79M	0.05%	88

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Paulson & Co's BPMC Position: Q3 2017 in Review

Paulson & Co sold out of Blueprint Medicines (BPMC) in Q3 2017, closing a stake of 65,800 shares — an estimated $3.33M sold.

Paulson & Co first reported a position in BPMC in Q2 2017 and held it in 1 quarter. The position peaked at $3.33M in Q2 2017. 138 funds tracked by Wall St. Rank hold BPMC as of Q3 2017.

Paulson & Co reported no remaining Blueprint Medicines position as of Q3 2017 after selling out during the quarter.
Paulson & Co sold 65,800 Blueprint Medicines shares in Q3 2017, an estimated $3.33M.
Paulson & Co first reported a position in Blueprint Medicines in Q2 2017 and held it in 1 quarter.
Paulson & Co's Blueprint Medicines position peaked at $3.33M in Q2 2017.
138 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2017.

Based on Paulson & Co's 13F filing for Q3 2017, filed 14 Nov 2017.